Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 65 years old, including women of childbearing age
- People who have been diagnosed with a form of psychosis (either affective or non-affective), as defined by specific international diagnostic codes (ICD-10 codes F20–30 and F32.3)
- People who are able to understand the study and have signed a written consent form agreeing to take part
- People who are willing to provide blood samples as part of the study
- People who are willing to provide saliva and stool (faecal) samples for testing
- People who are currently taking certain psychiatric medications — including antidepressants, mood stabilisers (such as lithium, valproate, or carbamazepine), sleeping tablets, or benzodiazepines — may still be considered, as these are permitted in the study
Who may not be able to join:
- People who use drugs intravenously (injected into a vein)
- People who have been diagnosed with substance dependence within the past 3 months
- People who are pregnant or planning to become pregnant
- People who have taken antibiotics in the past 30 days
- People who have used steroid medications in the past 30 days
- People who have used blood thinners, anti-inflammatory drugs, over-the-counter pain relievers (such as NSAIDs like ibuprofen), or other analgesics — a 4-week washout period without these medications would be required (confirm with trial site)
- People living with a serious or unstable medical condition, including congestive heart failure, coeliac disease, or an immune deficiency condition
- People who have taken probiotic or prebiotic supplements within the past 30 days
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Harriet Schellekens, PhD, University College Cork
Phone: + 353 (0) 21 420 5429
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Bifidobacterium longum on weight gain; Bifidobacterium longum on glucose levels.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.